文献速递甲状腺疾病

桥本甲状腺炎患者甲状腺DPP4表达升高与炎症过程相关

Increased Thyroid DPP4 Expression Is Associated With Inflammatory Process in Patients With Hashimoto Thyroiditis.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

本病例对照研究纳入40例未用药桥本甲状腺炎(HT)患者和81例对照,评估外周血与甲状腺组织中二肽基肽酶-4(DPP4)的表达和活性,并结合单细胞RNA测序与体外实验。HT组甲状腺DPP4表达和活性显著高于对照组,主要定位于T细胞;西格列汀抑制淋巴细胞DPP4活性可下调共培养甲状腺细胞炎症因子产生。

要点

  • HT患者与对照的血清DPP4浓度和活性相似。
  • HT组甲状腺DPP4表达和活性显著高于对照组。
  • 抑制淋巴细胞DPP4活性可减少共培养甲状腺细胞炎症因子产生。

核心结论

  • HT组甲状腺DPP4表达显著高于对照组,且主要定位于淋巴细胞。
  • 抑制淋巴细胞DPP4活性可减少共培养甲状腺细胞炎症因子产生。
  • 作者认为抑制DPP4可能通过减轻HT患者炎症反应产生有益作用。

研究设计与样本

  • 病例对照研究纳入40例未用药HT患者和81例对照个体。
  • 采集外周血和甲状腺标本评估DPP4表达与活性。
  • 对scRNA-seq数据集GSE184362中6例「瘤旁组织」样本进行单细胞RNA测序分析,并开展体外细胞实验。

主要发现

  • HT患者与对照的血清DPP4浓度和活性相似。
  • HT组甲状腺DPP4表达和活性显著高于对照组。
  • scRNA-seq分析显示HT组DPP4表达显著升高,主要表达于T细胞。
  • 体外研究显示,用西格列汀抑制淋巴细胞DPP4活性可下调共培养甲状腺细胞炎症因子的产生。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Dipeptidyl peptidase-4 (DPP4) is originally described as a surface protein in lymphocytes. Lymphocyte infiltration and subsequent destruction of thyroid tissue have been considered as the central pathological mechanism in Hashimoto thyroiditis (HT). OBJECTIVE: The present study aimed to investigate DPP4 expression in peripheral blood and thyroid tissue in HT patients, and explore the role of DPP4 in the pathophysiological process of HT. METHODS: This case-control study recruited 40 drug-naive HT patients and 81 control individuals. Peripheral blood and thyroid specimens were collected for assessing the expression and activity of DPP4. Moreover, single-cell RNA sequencing (scRNA-seq) analysis of 6 "para-tumor tissues" samples from scRNA-seq data set GSE184362 and in vitro cell experiments were also conducted. RESULTS: The HT patients had similar DPP4 serum concentration and activity as the controls. However, the expression and activity of DPP4 was significantly increased in the thyroid of the HT group than in the control group. The scRNA-seq analysis showed that DPP4 expression was significantly increased in the HT group, and mainly expressed in T cells. Further in vitro studies showed that inhibition of lymphocyte DPP4 activity with sitagliptin downregulated the production of inflammatory factors in co-cultured thyroid cells. CONCLUSION: DPP4 expression was significantly increased in the thyroid of the HT group compared with the control group, and was mainly localized in the lymphocytes. Inhibition of lymphocyte DPP4 activity reduced the production of inflammatory factors in co-cultured thyroid cells. Therefore, inhibition of DPP4 may have a beneficial effect by alleviating inflammatory reactions in HT patients.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wen X, Chang X, He X, et al. Increased Thyroid DPP4 Expression Is Associated With Inflammatory Process in Patients With Hashimoto Thyroiditis. J Clin Endocrinol Metab. 2024. PMID: 38127960. doi:10.1210/clinem/dgad723

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。